$15 drug gets COVID patients off oxygen support in under week – study
Fenofibrate could dramatically shorten the treatment time for severe COVID patients
Fourteen out of 15 severe COVID-19 patients who were treated in an investigator-initiated interventional open-label clinical study of the drug TriCor (fenofibrate) didn’t require oxygen support within a week of treatment and were released from the hospital, according to the results of a new Hebrew University of Jerusalem study.
Fenofibrate is an FDA-approved oral medication. The results were published on Researchsquare.com and are currently under peer review.-- More...
Read next: Blockbuster Yale Study: Millions Of Long COVID Patients Might Actually Be Vaccine Injured
